Alumis Inc. ALMS 深 滬
等待開盤 05-19 09:30:00 美东时间
21.15
-1.720
-7.52%
華盛通- 最 高23.39
- 今 開23.06
- 成交量 128.14万股
- 最 低 20.53
- 昨 收 22.87
- 總市值 269.65万
- 52周最高 30.60
- 市盈率 靜 --
- 換手率 1.01%
- 52周最低 2.7601
- 委 比 24.53%
- 總股本 0.00亿
- 歷史最高 30.60
- 量 比 1.66
- 振 幅 12.51%
- 歷史最低 2.7601
- 每 手 1
- 風險率 9.82%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 应用材料获17家大行集体上调目标价；Bitdeer 、Forgent 、嘉信理财、Viking等获多家大行上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从11美元升至12美元；Ladenburg Thalmann：维持Usio"买入"评级，目标价从5.75美元升至6.25美元
05-18 11:48
HC Wainwright & Co. Downgrades Alumis to Neutral, Maintains Price Target to $25
HC Wainwright & Co. analyst Mitchell S. Kapoor downgrades Alumis (NASDAQ:ALMS) from Buy to Neutral and maintains the price target from $25 to $25.
05-15 18:42
Alumis Q1 EPS $(0.74) Beats $(0.77) Estimate, Sales $1.741M Miss $2.767M Estimate
Alumis (NASDAQ:ALMS) reported quarterly losses of $(0.74) per share which beat the analyst consensus estimate of $(0.77) by 3.9 percent. This is a 59.34 percent increase over losses of $(1.82) per share from the same
05-15 04:51
Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements
Alumis Inc. reported positive Phase 3 data for envudeucitinib in moderate-to-severe plaque psoriasis, showing robust PASI 90 (68.0% and 62.1%) and PASI 100 (41.0% and 39.5%) responses by Week 16 and 24, respectively. The company plans to submit an NDA for envudeucitinib in 4Q 2026 and anticipates pivotal Phase 2b data for systemic lupus erythematosus (SLE) in 3Q 2026. Financially, Alumis ended Q1 2026 with $569.5 million in cash and marketable se...
05-14 20:05
美股大行评级 | 潜在涨幅172.14%！Alumis获Oppenheimer上调目标价至55美元；摩根大通首予希捷科技"超配"评级，目标价525美元
今日重点评级关注：Oppenheimer：维持Alumis"跑赢大市"评级，目标价从50美元升至55美元；美银证券：维持Rocket Pharmaceuticals"买入"评级，目标价从8美元升至9美元
03-31 16:30
Why Is Alumis Stock Falling Monday?
ALMS stock drops 11% as investors lock in a 239% yearly gain. Analyze the support levels and technical indicators for Alumis Inc. (NASDAQ).
03-31 00:54
Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis
Alumis Inc. reported positive results from its Phase 3 trials of envudeucitinib, a TYK2 inhibitor for moderate-to-severe plaque psoriasis, showing robust PASI 90 and 100 responses by Week 16 and continued improvements by Week 24. The drug demonstrated early onset of action, improving quality of life and itch relief ahead of skin clearance, with significant benefits in scalp psoriasis. Envudeucitinib also exhibited a favorable safety profile. The ...
03-28 17:30
美股大行评级 | 小摩、瑞穗等下调阿里目标价最低至164美元；达登饭店、联邦快递、林肯教育服务、Planet Labs等获多家大行上调目标价
今日重点评级关注：瑞穗：维持RELMADA THERAPEUTICS"跑赢大市"评级，目标价从10美元升至19美元；奥本海默：维持Pelthos Therapeutics"跑赢大市"评级，目标价从60美元升至62美元
03-23 13:53
Alumis Q4 Sales $1.929M Miss $2.833M Estimate
Alumis (NASDAQ:ALMS) reported quarterly sales of $1.929 million which missed the analyst consensus estimate of $2.833 million by 31.92 percent.
03-20 04:26
Alumis Says Results From Phase 3 ONWARD Program Evaluating Envudeucitinib Accepted For Late-Breaking Oral Presentation, And New Biomarker Analysis From Phase 2 STRIDE Trial Of Envudeucitinib Accepted As E-Poster At AAD 2026
– Phase 3 data presentation highlighting results from the ONWARD1 and ONWARD2 clinical trials of envudeucitinib –– Phase 2 STRIDE e-poster presentation to describe disease biomarker activity of envudeucitinib ––
03-18 20:08
